CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is supported by Casgevy’s commercial momentum and the company’s ability to pair an approved therapy with a deep pipeline in gene editing, immuno-oncology, cardiovascular disease, and Type 1 diabetes. Its outlook is strengthened by CTX310’s durable one-year data, including a mean 78.6% reduction in ANGPTL3 at the highest dose, plus favorable safety with no recurrent ALT/AST elevations and no new serious treatment-related events, which supports a differentiated one-time approach in lipid-lowering. The bull case also benefits from expectations that Casgevy sales can exceed expectations and that earlier-stage programs could reach commercialization or attract acquisition interest, while the base case assumes Casgevy exceeds $1B in global sales by 2030.

CRISPR Therapeutics is viewed negatively because its investment case depends on a highly uncertain CRISPR/Cas9 intellectual property landscape, heavy reliance on third-party patent rights, and a pipeline exposed to meaningful clinical, regulatory, and development risk. While CTX310 and related programs showed strong biomarker reductions, the data were inconsistent and sometimes unstable over 12 months, with small cohorts and variable triglyceride responses raising durability concerns. In addition, Casgevy sales may fail to accelerate, partnerships with Vertex and Bayer could shift unfavorably, and the company may need additional equity financing, creating dilution risk for shareholders.